

TriAltus Bioscience Launches Custom CLiM™ – Based Protein Purification Services

BIRMINGHAM, ALABAMA, UNITED STATES, November 23, 2021 /EINPresswire.com/ -- TriAltus Bioscience, LLC today launched its new CLiM Affinity Tag System as a service. The ultra-high-affinity (CL7/Im7) purification system allows for HHH purification of a wide range of challenging biological molecules, including eukaryotic, membrane, toxic, and DNA/RNA-binding proteins and complexes. The system brings significant benefit to advanced structural and industrial applications as well as gene therapy research.

TriAltus' custom protein production service offers research labs an extension of their in-house teams, streamlining research and ensuring optimal outcomes. Our custom purification and expression team can deliver a clone of the desired DNA into an expression vector, protein expression of the desired expression construct and [protein purification](#) via our proprietary CLiM technology. We partner with customers at every stage of the discovery and development process to design and generate proteins that support their projects from initial research to clinical application.

Robert Shufflebarger, Co-founder and CEO of TriAltus Biosciences, reflected on the company's recent move, commenting that "Our Affinity Tag System-as-a-Service represents an important new approach to supporting our customers' research efforts. By providing scientists with customized solutions that remove bottlenecks in the protein purification process, we can help them advance their research portfolios."

###

About TriAltus Bioscience

TriAltus develops innovative tools for the production and purification of genetically engineered proteins. Our novel affinity tag system delivers proteins with ultra-high purity and yield in a single step. Having proven the CLiM technology on some extremely difficult proteins, TriAltus is actively developing R&D partnerships to use CLiM to purify proteins for customer-defined projects.

For more information, visit trialtusbioscience.com

Contact: Tom Round

Vice President, Business Development TriAltus Bioscience, LLC

tom round

TriAltus Bioscience

+1 626-827-1164

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/556988470>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.